問卷

TPIDB > Search Result

Search Result

篩選

List

588Cases

2019-08-01 - 2022-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-08-01 - 2025-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-01-01 - 2020-12-31

Phase II

Topography Staging and Dual Phase Image Quantification of Tau PET in Cognitive Impairment Subjects
  • Condition/Disease

    Alzheimer's disease

  • Test Drug

    18F-PMPBB3

Participate Sites
2Sites

Recruiting2Sites

2019-08-01 - 2022-07-31

Phase II

A noval tau tracer ([ 18F]PM-PBB3) in young onset dementia: clinical and neuroimaging study
  • Condition/Disease

    *PRESENILE DEMENTIA;SENILE DEMENTIA, UNCOMPLICATED;DEMENTIA IN CONDITIONS CLASSIFIED ELSEWHERE;AMNESTIC  SYNDROME

  • Test Drug

    (1)[F18] AV-45 (2) [F-18] PM-PBB3

Participate Sites
3Sites

Recruiting3Sites

2018-09-21 - 2028-11-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-01-01 - 2023-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-12-31 - 2023-12-31

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    Tildrakizumab

Participate Sites
9Sites

Recruiting9Sites

2020-09-01 - 2024-05-31

Phase III

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.
  • Condition/Disease

    Relapsing Multiple Sclerosis

  • Test Drug

    Evobrutinib

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting2Sites

Terminated1Sites

2021-05-31 - 2024-12-31

Phase III

A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (Sotorasib) for the Treatment of Subjects with Previously Treated Locally Advanced Unresectable/Metastatic NSCLC with KRAS p.G12C Mutation
  • Condition/Disease

    Non Small-cell Lung Cancer

  • Test Drug

    AMG 510 (Sotorasib)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2021-04-01 - 2024-05-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites